Ocugen

Ocugen is a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. It is headquartered in Malvern, Pennsylvania.
Ocugen stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Ocugen balance sheet

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Ocugen cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Ocugen multipliers

Report period2017 2018 2019 2020 2021 2022
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Ocugen profitability

Report period2017 2018 2019 2020 2021 2022
ROA
ROE
ROS
EBITDA Margin
Operating margin
Ocugen assets
Ocugen cash flows

Ocugen dividend policy

The company doesn't provide dividends

Ocugen shares

TickerNameTypeNominal valueISINPrice
OCGN:USOcugenCommon share-US67577C1053$1.32
Ocugen news
08.05.2022
Ocugen's GAAP loss for 3 months of 2022 was $18.019 million, up 2.6 times from $7.077 million in the previous year.
Source: {source} pictogram ir.ocugen.com
Pictogram next
04.03.2022
FDA has denied FDA approval of Ocugen's emergency use of COVAXIN to prevent COVID-19 in persons aged 2 to 18 years. The company will continue to work with the FDA to evaluate the regulatory mechanism for pediatric use of the drug.
Source: {source} pictogram ocugen.gcs-web.com
Pictogram next
26.11.2021
The FDA has suspended clinical trials of BBV152, the COVID-19 vaccine from Ocugen known outside the United States under the brand name COVAXIN. The regulator will report specific trial shortcomings and instructions on how to correct them at a later date.
Source: {source} pictogram ocugen.gcs-web.com
Pictogram next
09.11.2021
Ocugen's GAAP loss for 9M 2021 was $43.784 million, up 2.4 times from $18.032 million in the prior year.
Source: {source} pictogram ir.ocugen.com
Pictogram next
All Ocugen news
General information
Company nameOcugen
Tags#biotechnology, #genome
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address263 Great Valley Parkway Suite 160 Malvern, PA 19355 United States
Mailing address263 Great Valley Parkway Suite 160 Malvern, PA 19355 United States
Websiteir.ocugen.com